BOSTON — Sensory Cloud Inc. announced it has completed enrollment in its Phase 2a REACH trial, which is evaluating SC0023, an investigational inhaled therapy for refractory chronic cough (RCC). Affecting an estimated 9 million Americans, RCC currently lacks safe and effective first-line treatment options.
The REACH study is assessing SC0023, a proprietary aerosolized alkaline hypertonic divalent salt (HDS) formulation, designed to deactivate inflammatory pathways in the upper airway that contribute to cough hypersensitivity. SC0023 incorporates ions and buffers naturally found in human airways, aiming to reduce persistent cough triggered by environmental factors such as atmospheric dryness.
“REACH is designed to help clarify the therapeutic potential of this new class of inhaled treatments for refractory chronic cough,” said Dr. Kian Fan Chung, Professor of Respiratory Medicine at Imperial College London and co-investigator on the study. “This approach is unique among current investigational programs advancing in clinical trials.”
The trial is a randomized, double-blind, placebo-controlled crossover study conducted at King Saud University Medical City in Saudi Arabia. Participants receive SC0023 or placebo in two 14-day treatment periods, with continuous digital cough monitoring and post-treatment follow-up extending up to three weeks. Investigators are evaluating changes in cough frequency as well as patient-reported outcomes.
The study is led by principal investigators Dr. Kholood Altassan and Dr. Beshayr Alotaibi and has received institutional approval from the Saudi Food and Drug Administration and an independent review board.
Sensory Cloud’s founder and CEO, Dr. David A. Edwards, will present new data on SC0023’s mechanism of action at the American Thoracic Society Meeting in San Francisco on May 17. The presentation is expected to provide further insight into how daily use of SC0023 may alleviate cough sensitivity linked to inflammatory responses in increasingly dry air environments.
Top-line results from the REACH trial are expected in early Q3 2025.
